Cargando…

Normal Alpha-1-Antitrypsin Variants Display in Serum Allele-Specific Protein Levels

[Image: see text] Alpha-1-antitrypsin (A1AT or SERPINA1) has been proposed as a putative biomarker distinguishing healthy from diseased donors throughout several proteomics studies. However, the SERPINA1 gene displays high variability of frequent occurring genotypes among the general population. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Jager, Shelley, Cramer, Dario A. T., Heck, Albert J. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088046/
https://www.ncbi.nlm.nih.gov/pubmed/36946534
http://dx.doi.org/10.1021/acs.jproteome.2c00833
_version_ 1785022488790433792
author Jager, Shelley
Cramer, Dario A. T.
Heck, Albert J. R.
author_facet Jager, Shelley
Cramer, Dario A. T.
Heck, Albert J. R.
author_sort Jager, Shelley
collection PubMed
description [Image: see text] Alpha-1-antitrypsin (A1AT or SERPINA1) has been proposed as a putative biomarker distinguishing healthy from diseased donors throughout several proteomics studies. However, the SERPINA1 gene displays high variability of frequent occurring genotypes among the general population. These different genotypes may affect A1AT expression and serum protein concentrations, and this is often not known, ignored, and/or not reported in serum proteomics studies. Here, we address allele-specific protein serum levels of A1AT in donors carrying the normal M variants of A1AT by measuring the proteoform profiles of purified A1AT from 81 serum samples, originating from 52 donors. When focusing on heterozygous donors, our data clearly reveal a statistically relevant difference in allele-specific protein serum levels of A1AT. In donors with genotype PI*M1VM1A, the experimentally observed ratio was approximately 1:1 (M1V/M1A, 1.00:0.96 ± 0.07, n = 17). For individuals with genotype PI*M1VM2, this ratio was 1:1.28 (M1V/M2, 1.00:1.31, ±0.19, n = 7). For genotypes PI*M1VM3 and PI*M1AM3, a significant higher amount of M3 was observed compared to the M1-subtypes (M1V/M3, 1.00:1.84 ± 0.35, n = 8; M1A/M3, 1.00:1.61 ± 0.33, n = 5). We argue that these observations are important and should be considered when analyzing serum A1AT levels before proposing A1AT as a putative serum biomarker.
format Online
Article
Text
id pubmed-10088046
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-100880462023-04-12 Normal Alpha-1-Antitrypsin Variants Display in Serum Allele-Specific Protein Levels Jager, Shelley Cramer, Dario A. T. Heck, Albert J. R. J Proteome Res [Image: see text] Alpha-1-antitrypsin (A1AT or SERPINA1) has been proposed as a putative biomarker distinguishing healthy from diseased donors throughout several proteomics studies. However, the SERPINA1 gene displays high variability of frequent occurring genotypes among the general population. These different genotypes may affect A1AT expression and serum protein concentrations, and this is often not known, ignored, and/or not reported in serum proteomics studies. Here, we address allele-specific protein serum levels of A1AT in donors carrying the normal M variants of A1AT by measuring the proteoform profiles of purified A1AT from 81 serum samples, originating from 52 donors. When focusing on heterozygous donors, our data clearly reveal a statistically relevant difference in allele-specific protein serum levels of A1AT. In donors with genotype PI*M1VM1A, the experimentally observed ratio was approximately 1:1 (M1V/M1A, 1.00:0.96 ± 0.07, n = 17). For individuals with genotype PI*M1VM2, this ratio was 1:1.28 (M1V/M2, 1.00:1.31, ±0.19, n = 7). For genotypes PI*M1VM3 and PI*M1AM3, a significant higher amount of M3 was observed compared to the M1-subtypes (M1V/M3, 1.00:1.84 ± 0.35, n = 8; M1A/M3, 1.00:1.61 ± 0.33, n = 5). We argue that these observations are important and should be considered when analyzing serum A1AT levels before proposing A1AT as a putative serum biomarker. American Chemical Society 2023-03-22 /pmc/articles/PMC10088046/ /pubmed/36946534 http://dx.doi.org/10.1021/acs.jproteome.2c00833 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Jager, Shelley
Cramer, Dario A. T.
Heck, Albert J. R.
Normal Alpha-1-Antitrypsin Variants Display in Serum Allele-Specific Protein Levels
title Normal Alpha-1-Antitrypsin Variants Display in Serum Allele-Specific Protein Levels
title_full Normal Alpha-1-Antitrypsin Variants Display in Serum Allele-Specific Protein Levels
title_fullStr Normal Alpha-1-Antitrypsin Variants Display in Serum Allele-Specific Protein Levels
title_full_unstemmed Normal Alpha-1-Antitrypsin Variants Display in Serum Allele-Specific Protein Levels
title_short Normal Alpha-1-Antitrypsin Variants Display in Serum Allele-Specific Protein Levels
title_sort normal alpha-1-antitrypsin variants display in serum allele-specific protein levels
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088046/
https://www.ncbi.nlm.nih.gov/pubmed/36946534
http://dx.doi.org/10.1021/acs.jproteome.2c00833
work_keys_str_mv AT jagershelley normalalpha1antitrypsinvariantsdisplayinserumallelespecificproteinlevels
AT cramerdarioat normalalpha1antitrypsinvariantsdisplayinserumallelespecificproteinlevels
AT heckalbertjr normalalpha1antitrypsinvariantsdisplayinserumallelespecificproteinlevels